Filtered By:
Drug: Lipitor

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 875 results found since Jan 2013.

DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE < sup > -/- < /sup > mice via suppressing inflammation, endothelial necroptosis and apoptosis
This study aims to explore whether NBP is able to improve endothelium-dependent vasodilation in atherosclerosis and the underlying mechanisms. Male ApoE-/- mice were fed with a high-fat diet (HFD) for 9-16 weeks to establish a model of atherosclerosis. NBP were given to the mice after eating HFD for 6 weeks and atorvastatin served as a positive control. The endothelium-dependent vasodilation, the blood flow velocity, the atherosclerotic lesion area, the serum levels of lipids, inflammatory cytokines and necroptosis-relevant proteins (RIPK1, RIPK3 and MLKL), and the endothelial necroptosis and apoptosis within the aorta wer...
Source: Atherosclerosis - August 3, 2023 Category: Cardiology Authors: Li-Qun Lu Nian-Sheng Li Ming-Rui Li Jiao-Yang Peng Li-Jing Tang Xiu-Ju Luo Jun Peng Source Type: research

Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy Effect of Baseline Risk Factors for Diabetes
ConclusionsCompared with lower-dose statin therapy, atorvastatin 80 mg/day did not increase the incidence of NOD in patients with 0 to 1 NOD risk factors but did, by 24%, among patients with 2 to 4 NOD risk factors. The number of CV events was significantly reduced with atorvastatin 80 mg in both NOD risk groups.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 7, 2013 Category: Cardiology Source Type: research

Comparison of Rosuvastatin versus Atorvastatin for Preventing Postoperative Atrial Fibrillation.
Conclusions: The present study revealed that preoperative rosuvastatin or atorvastatin treatment did not have a different effect in preventing postoperative AF. PMID: 23803242 [PubMed - in process]
Source: The Heart Surgery Forum - June 1, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Abaci O, Kocas C, Oktay V, Yildiz CE, Kilickesmez KO, Coskun U, Yildiz A, Yigit Z Tags: Heart Surg Forum Source Type: research

C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate with Coronary Atheroma Regression and Cardiovascular Events Following Maximally Intensive Statin Therapy.
CONCLUSIONS: Following 24 months of potent statin therapy, on-treatment CRP levels associated with MACE. Inflammation may be an important driver of residual cardiovascular risk in patients with coronary artery disease despite aggressive statin therapy. CLINICAL TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov. Identifier: NCT000620542. PMID: 24043299 [PubMed - as supplied by publisher]
Source: Circulation - September 16, 2013 Category: Cardiology Authors: Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ Tags: Circulation Source Type: research

Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy
Conclusion Following 2 years of high-intensity statin therapy, a baseline coronary atheroma volume predicted MACE, despite the achievement of very low on-treatment LDL-C levels.
Source: European Heart Journal - November 1, 2013 Category: Cardiology Authors: Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R., Libby, P., Raichlen, J. S., Uno, K., Kataoka, Y., Nicholls, S. J. Tags: Coronary artery disease Source Type: research

Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
CONCLUSIONS: This study found that switching from rosuvastatin to atorvastatin led to fewer patients attaining LDL-C goal and a greater risk for MACE. PMID: 24417785 [PubMed - in process]
Source: Clinical Therapeutics - January 1, 2014 Category: Drugs & Pharmacology Authors: Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S Tags: Clin Ther Source Type: research

The Inhibitory Effect of Simvastatin and Aspirin on Histamine Responsiveness in Human Vascular Endothelial Cells.
Abstract Statins and aspirin deliver well-established cardiovascular benefits resulting in their increased use as combined polypills to decrease risk of stroke and heart disease. However, the direct endothelial effect of combined statin/aspirin cotreatment remains unclear. Histamine is an inflammatory mediator that increases vascular permeability and so we examined the effect of treating human umbilical vein endothelial cells (HUVECs) for 24-hours with 1μM simvastatin and 100μM aspirin on histamine responsiveness. Subsequent histamine (1μM) challenge increased Ca(2+)i concentration, an effect that was significa...
Source: Am J Physiol Cell Ph... - January 29, 2014 Category: Cytology Authors: Absi M, Bruce JI, Ward DT Tags: Am J Physiol Cell Physiol Source Type: research

The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Abstract: Background: Current guidelines recommend intensive low-density lipoprotein (LDL) cholesterol lowering with statins, with a target of 70mg/dL (1.81mmol/L) LDL cholesterol for those with a very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid-lowering therapy with statins on acute coronary syndrome (ACS) in a Chinese population with low baseline LDL cholesterol levels.Methods and results: Patients (n=1355) with ACS were treated with a moderate dose of statin (atorvastatin 10 mg/d, or equivalent dose of other statins, n=675) or with an intensive dose...
Source: Atherosclerosis - March 20, 2014 Category: Cardiology Authors: Shui-ping Zhao, Bi-lian Yu, Dao-quan Peng, Yong Huo Tags: Clinical & Population Research – Intervention Source Type: research

The inhibitory effect of simvastatin and aspirin on histamine responsiveness in human vascular endothelial cells
Statins and aspirin deliver well-established cardiovascular benefits resulting in their increased use as combined polypills to decrease risk of stroke and heart disease. However, the direct endothelial effect of combined statin/aspirin cotreatment remains unclear. Histamine is an inflammatory mediator that increases vascular permeability, and so we examined the effect of treating human umbilical vein endothelial cells (HUVECs) for 24 h with 1 μM simvastatin and 100 μM aspirin on histamine responsiveness. Subsequent histamine (1 μM) challenge increased intracellular calcium (Ca2+i) concentration, an effect that was...
Source: AJP: Cell Physiology - April 1, 2014 Category: Cytology Authors: Absi, M., Bruce, J. I., Ward, D. T. Tags: ARTICLES Source Type: research

Atorvastatin improves systolic function, but does not prevent the development of dilated cardiomyopathy in streptozotocin-induced diabetic rats
Conclusions: Whereas atorvastatin does not reverse ventricular dilatation, it does have a positive hemodynamic effect on the CV system of diabetic rats. This hemodynamic benefit is independent of cholesterol levels, and is observed concomitantly with reduced oxidative stress, vascular remodeling, and improved endothelial function. Together, these results suggest that atorvastatin decreases the workload on the heart and improves systolic performance in type 1 diabetic rats by reducing oxidative stress, vascular tone, and systemic vascular resistance.
Source: Therapeutic Advances in Cardiovascular Disease - June 11, 2014 Category: Cardiology Authors: Quidgley, J., Cruz, N., Crespo, M. J. Tags: Original Research Source Type: research

Glun2b N‐methyl‐D‐aspartic acid receptor subunit mediates atorvastatin‐Induced neuroprotection after focal cerebral ischemia
This study evaluates whether atorvastatin (ATV) treatment affects the GluN1 and GluN2B subunits of the N‐methyl‐D‐aspartic acid receptor in the somatosensory cerebral cortex at short and long periods following ischemia. Sham and ischemic male Wistar rats received 10 mg/kg of ATV or placebo by gavage every 24 hr for 3 consecutive days. The first dose was administered 6 hr after ischemia–reperfusion or the sham operation. ATV treatment resulted in faster recovery of neurological scores than placebo, prevented the appearance of pyknotic neurons, and restored microtubule‐associated protein 2 and neuronal nuclei stain...
Source: Journal of Neuroscience Research - June 17, 2014 Category: Neuroscience Authors: Johanna Andrea Gutierrez‐Vargas, Juan Ignacio Muñoz‐Manco, Luis Miguel Garcia‐Segura, Gloria Patricia Cardona‐Gómez Tags: Research Article Source Type: research

Statins - Are they anticonvulsant?
Abstract Statins are the most popular and effective lipid-lowering medications beneficial in hypercholesterolemias and prevention of cardiovascular diseases. Growing evidence supports theory that statins exhibit neuroprotective action in acute stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis or epilepsy. Hereby, we present available experimental data regarding action of this group of drugs on seizure activity and neuronal cell death. The most commonly examined statins, such as atorvastatin and simvastatin, display anticonvulsant action with only inconsiderable exceptions. However, the mechanism...
Source: Pharmacological Reports - June 22, 2014 Category: Drugs & Pharmacology Authors: Banach M, Czuczwar SJ, Borowicz KK Tags: Pharmacol Rep Source Type: research

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial
Conclusion In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
Source: European Heart Journal - July 15, 2014 Category: Cardiology Authors: Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D., Deedwania, P., Kostis, J. B., Messerli, F. H., Treating to New Targets Steering Committee and Investigators Tags: Heart failure/cardiomyopathy Source Type: research

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Publication date: Available online 7 August 2014 Source:American Heart Journal Author(s): Gregory G. Schwartz , Laurence Bessac , Lisa G. Berdan , Deepak L. Bhatt , Vera Bittner , Rafael Diaz , Shaun G. Goodman , Corinne Hanotin , Robert A. Harrington , J. Wouter Jukema , Kenneth W. Mahaffey , Angèle Moryusef , Robert Pordy , Matthew T. Roe , Tyrus Rorick , William J. Sasiela , Cheerag Shirodaria , Michael Szarek , Jean-François Tamby , Pierluigi Tricoci , Harvey White , Andreas Zeiher , Philippe Gabriel Steg Following acute coronary syndrome (ACS), the risk for future cardiovascular events is high and is related to le...
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research